Shots:
- The P-III (LATITUDE) trial assessed Cabenuva (cabotegravir + rilpivirine) in 453 adults facing adherence challenges, where 306 virally suppressed pts were randomized to Cabenuva (Q4W; n=152) or ART (QD, PO; n=154), with results published in The NEJM
- At 48wks., Cabenuva reduced the cumulative risk of regimen failure (1EP) to 22.8% vs 41.2%, with fewer virologic failures & treatment discontinuations observed in the injectable arm
- Virologic failure occurred in 6.8% vs 28.2% (cumulative probability), & treatment-related failure in 8.9% vs 28.1%, while permanent discontinuation of treatment occurred in 19.8% vs 28.2%; ViiV is also conducting the CROWN study of Cabenuva against daily oral therapy in pts with adherence challenges & detectable virus
Ref: GSK | Image: ViiV Healthcare | Press Release
Related News: GSK and Shionogi Restructure ViiV Healthcare Ownership as Pfizer Exits
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
